Experts Discuss How to Address Cardiac-Related Toxicities With EGFR TKIs

EP: 1.Emily Skotte, MSN on Rash Management in Patients Treated With EGFR TKIs

EP: 2.Dr. Cass on Managing Diarrhea in Patients Treated With EGFR TKIs

EP: 3.Dr. Piotrowska on the Management of Paronychia Associated With EGFR TKIs

EP: 4.Best Practices for Managing EGFR Tyrosine Kinase Inhibitor–Related Adverse Events

EP: 5.Experts Discuss Management of Skin and Mouth TRAEs Associated With EGFR TKIs

EP: 6.Experts Discuss the Risk of Skin Toxicities Associated With EGFR TKIs

EP: 7.Experts Discuss Common AEs With EGFR TKIs

EP: 8.Experts Discuss the Safety Profile of Mobocertinib in EGFR Exon 20–Mutated Advanced NSCLC

Now Viewing

EP: 9.Experts Discuss How to Address Cardiac-Related Toxicities With EGFR TKIs

EP: 10.Experts Discuss the Management of Paronychia When Treating Patients with EGFR TKIs

EP: 11.Experts on the Management of Diarrhea Associated With EGFR TKIs

Gregory Riely, MD, and Shirish Gadgeel, MD, discuss how to address cardiac-related toxicities associated with treatment with EGFR TKIs.

Gregory Riely, MD, is a medical oncologist in the Department of Medicine at Memorial Sloan Kettering Cancer Center. Shirish Gadgeel, MD, is the co-leader of the Thoracic Oncology Research Program and a Mary Lou Kennedy Research Professor at the University of Michigan.

Riely and Gadgeel explain their monitoring habits for cardiac-related toxicities with EGFR TKIs. Baseline EKG and echocardiograms are necessary, as are intermittent echocardiograms when patients are on treatment.

As more data become available for patients being treated with the EGFR TKI mobocertinib (Exkivity), it is expected that the overall understanding of cardiac toxicities will be refined. Moreover, patient education is vital for them to understand their symptoms and management options for cardiac toxicities.